Call Us: 888-488-5750

Innovative Revenue Solutions in Healthcare:​

VativoRx CEO Lisa Quarterman's Insights in the Solutions Spotlight Series

The Hospital and Healthsystem Association of Pennsylvania

Our CEO, Lisa Quarterman, recently joined the Solutions Spotlight series to chat with HAPevolve President Joe Tibbs. In this series, Lisa explains how VativoRx can help deliver additional revenue to hospitals, outpatient facilities, and other healthcare organizations without any additional expense or changes to their contracts.

VativoRx is an exclusive vendor for the Hospital and Healthsystem Association of Pennsylvania (HAP). HAPevolve identifies and creates valuable partnerships with a variety of businesses serving the healthcare community. By negotiating with its industry and endorsed partners on behalf of the Pennsylvania hospital and healthcare community at large, HAPevolve can offer members special benefits and discounts on innovative solutions that can save them both time and money.

Maximize Your Rebate Revenue with Expertise and Innovation.

Prioritizing Data Integrity, Rigorous Compliance, and Top-tier Security.

Unveiling the Future: Navigating the Evolving Landscape of 340B Rebates.

The 340B Drug Pricing Program, established in 1992, has been a crucial component of the healthcare system, dedicated to assisting eligible healthcare organizations in serving vulnerable patient populations by granting them access to discounted drugs. At the heart of this program are the 340B rebates, which enable qualifying entities such as safety-net hospitals, community health centers, and other eligible providers to acquire medications at significantly reduced prices.

Read More »
Martin Shields / Alamy Stock Photo

Humira – The End of an Era

In January 2023, the first biosimilar version of Humira, which is a widely used injectable drug for inflammatory diseases, was approved, marking the end of AbbVie’s two-decade market exclusivity. Humira is used to treat conditions like rheumatoid arthritis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis, and it works by targeting certain proteins in the immune system.

Read More »

Biosimilars — Similar But Not Identical

You may have never heard of biosimilar drugs and that’s probably because they are not commonly prescribed in the United States even though they have been around for over 20 years. So, what are biosimilar drugs? A biosimilar drug is no different in terms of safety and effectiveness than a biologic product, also known as a reference product, and while highly similar it is not identical.

Read More »